← Back to companies
United States · Lab robotics / AI chemistry CRO · privateThis company was auto-listed from our component database and has not yet had a full editorial review. The facts below come from supplier and product data; treat as unverified until reviewed.
Summary
U.S. chemistry CRO combining expert chemists, AI and robotics for drug-discovery compound synthesis/testing (lead-optimization analogs). No proprietary drug pipeline. Founders: Kevin Weil (ex-OpenAI CPO/VP Science), Sol Reisberg, Mano Paluri, DJ Patil. Early robotics hires from Genesis, Skild, 1X.
Key facts
Headquarters
San Francisco / South San Francisco, California
Founded
2026
Role
builder
Category
Healthcare
Sector
Lab robotics / AI chemistry CRO
Status
private
CEO
Kevin Weil
Funding
$215M Series A (Oct 2026) led by Lightspeed at $865M valuation (TechCrunch/Weil); IVP, Mayfield, Lux, Premji, Menlo et al.
Peers — same category & country
A
AS
AM
A
X
NH
SA
8R
Canada
AI
Hong Kong
AM
China
A
Switzerland
A
Japan
V
NetherlandsCapital
Funding
$215M Series A (Oct 2026) led by Lightspeed at $865M valuation (TechCrunch/Weil); IVP, Mayfield, Lux, Premji, Menlo et al.
Status
private
Investors
Primary-source investor lists stay on the interactive company profile. This page does not add investors that are not on the company record.
Figures as recorded by behindrobotics.com from company announcements, filings and market reporting. Verify before citing.